{"id":58,"date":"2020-07-17T12:30:00","date_gmt":"2020-07-17T12:30:00","guid":{"rendered":"https:\/\/nolato.wpengine.com\/?mfn_news=nolato-q2-2020-significant-sales-growth-and-good-earnings-performance-by-the-group"},"modified":"2020-07-17T12:30:00","modified_gmt":"2020-07-17T12:30:00","slug":"nolato-q2-2020-significant-sales-growth-and-good-earnings-performance-by-the-group","status":"publish","type":"mfn_news","link":"https:\/\/temporary.nolato.com\/sv\/mfn_news\/nolato-q2-2020-significant-sales-growth-and-good-earnings-performance-by-the-group\/","title":{"rendered":"Nolato Q2 2020: Significant sales growth and good earnings performance by the Group"},"content":{"rendered":"<div class=\"mfn-preamble\"><strong><\/strong><\/div>\n<ul>\n<li><span><span>Sales increased to SEK 2,307 million (1,987)<\/span><\/span><\/li>\n<li><span><span>Operating profit (EBITA) rose to SEK 269 million (233)<\/span><\/span><\/li>\n<li><span><span>EBITA margin of 11.7% (11.7)<\/span><\/span><\/li>\n<li><span><span>Profit after tax was SEK 207 million (180)<\/span><\/span><\/li>\n<li><span><span>Diluted earnings per share increased to SEK 7.79 (6.81)<\/span><\/span><\/li>\n<li><span><span>Cash flow after investment amounted to SEK 685 million (178)<\/span><\/span><\/li>\n<li><span><span>Sustained strong financial position<\/span><\/span><\/li>\n<\/ul>\n<p><span><span>\u201cAll three of our business areas performed well in the second quarter, given the current operating climate,\u201d said Nolato President and CEO Christer Wahlquist. \u201cThe strong sales growth and good earnings performance resulted in the quarter being the best ever in Nolato\u2019s history.\u201d<\/span><\/span><\/p>\n<p><span><span>Medical Solutions sales amounted to SEK 700 million (634); adjusted for currency, sales increased by a strong 9%. Operating profit rose to SEK 100 million (82) and the EBITA margin to a very strong 14.3% (12.9).<\/span><\/span><\/p>\n<p><span><span>\u201cMedical Solutions\u2019 overall performance was strong,\u201d noted Christer Wahlquist. \u201cProduction in some segments such as laboratory products and respiratory aids saw increased demand owing to the coronavirus situation. However, products in areas such as surgery were negatively affected as a result of fewer operations taking place.\u201d<\/span><\/span><\/p>\n<p><span><span>Integrated Solutions sales rose sharply to SEK 1,149 million (821); adjusted for currency and acquisitions, sales increased by a substantial 32%. Operating profit rose to SEK 166 million (107) and the EBITA margin was a very strong 14.4% (13.0).<\/span><\/span><\/p>\n<p><span><span>\u201cThe significant growth in Integrated Solutions continued in the quarter, in line with what has previously been communicated, driven in part by a build\u2010up of inventory by customers of vaporiser heating products (VHP),\u201d said Christer Wahlquist. \u201cInventory build\u2010up is expected to decrease in the third quarter, but with sustained healthy volumes. Performance in the EMC area has returned to normal levels and developed well, having been significantly affected by the coronavirus situation for parts of the first quarter.\u201d<\/span><\/span><\/p>\n<p><span><span>Industrial Solutions sales amounted to SEK 459 million (541); adjusted for currency, sales decreased by 16%. Operating profit decreased to SEK 11 million (46) and the EBITA margin to 2.4% (8.5).<\/span><\/span><\/p>\n<p><span><span>\u201cThe quarter began with our automotive industry customers halting operations as a result of the coronavirus,\u201d commented Christer Wahlquist. \u201cProduction has gradually come back on line since the middle of the quarter, but at much lower volumes than last year, with a significant impact on the business area\u2019s margin. New customer projects within general industry that started late last year are continuing to make a positive contribution to the business area\u2019s sales and profit.\u201d<\/span><\/span><\/p>\n<p><span><span>Cash flow after investment in the second quarter amounted to a very strong SEK 685 million (178). The financial position is strong, with net assets of SEK 1,245 million (190).<\/span><\/span><\/p>\n<p><span><span>For further information, please contact:<br \/>\nChrister Wahlquist, President and CEO, on +46 (0)705 804848<br \/>\nPer\u2010Ola Holmstr\u00f6m, CFO, on +46 (0)705 763340<\/span><\/span><\/p>\n<p><span><span>Nolato is a Swedish group with operations in Europe, Asia and North America. We develop and manufacture products in polymer materials such as plastic, silicone and TPE for leading customers within medical technology, pharmaceuticals, consumer electronics, telecom, automotive, hygiene and other selected industrial sectors. Nolato\u2019s shares are listed on Nasdaq Stockholm in the Large Cap segment, where they are included in the Industrials sector. www.nolato.com<\/span><\/span><\/p>\n<p><em><span><span>Prior to publication this information constituted inside information that Nolato AB is obliged to publish pursuant to the EU Market Abuse Regulation and the Swedish Securities Market Act. This information was submitted through the agency of the above contact persons for publication on 17 July 2020 at 2:30 p.m. CET.<\/span><\/span><\/em><\/p>\n<div class=\"mfn-footer\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sales increased to SEK 2,307 million (1,987) Operating profit (EBITA) rose to SEK 269 million (233) EBITA margin of 11.7% (11.7) Profit after tax was SEK 207 million (180) Diluted earnings per share increased to SEK 7.79 (6.81) Cash flow after investment amounted to SEK 685 million (178) Sustained strong financial position \u201cAll three of&hellip; <a class=\"more-link\" href=\"https:\/\/temporary.nolato.com\/sv\/mfn_news\/nolato-q2-2020-significant-sales-growth-and-good-earnings-performance-by-the-group\/\">Continue reading <span class=\"screen-reader-text\">Nolato Q2 2020: Significant sales growth and good earnings performance by the Group<\/span><\/a><\/p>\n","protected":false},"template":"","class_list":["post-58","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-report-interim","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-regulatory-mar","mfn-news-tag-mfn","mfn-news-tag-mfn-report-interim-q2","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-report","mfn-news-tag-mfn-regulatory-vpml","entry"],"translation":{"provider":"WPGlobus","version":"3.0.0","language":"sv","enabled_languages":["en","es","de","fr","ru","sv"],"languages":{"en":{"title":true,"content":true,"excerpt":false},"es":{"title":false,"content":false,"excerpt":false},"de":{"title":false,"content":false,"excerpt":false},"fr":{"title":false,"content":false,"excerpt":false},"ru":{"title":false,"content":false,"excerpt":false},"sv":{"title":false,"content":false,"excerpt":false}}},"_links":{"self":[{"href":"https:\/\/temporary.nolato.com\/sv\/wp-json\/wp\/v2\/mfn_news\/58","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/temporary.nolato.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/temporary.nolato.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/temporary.nolato.com\/sv\/wp-json\/wp\/v2\/media?parent=58"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}